Latest news
The Japanese Cancer Association and Debiopharm Group™ present Doctors Oshima and Tanaka with the 2012 ‘JCA-Mauvernay Award’ for their innovative…
Debiopharm Group presents the ‘Debiopharm Group Life Sciences Award 2012’ And two ‘Junior Debiopharm Group Life Sciences Awards 2012’ During…
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932 – Study to test Debio…
Debiopharm Group™ – First patient treated in Phase III study with subcutaneous administration of Debio 8206 for treatment of advanced…
Debiopharm Group is investing in Tweasy, the Saas e-marketing platform for SMEs
Debiopharm, Immunexpress and Biocartis Announce Collaboration to Advance Development of SeptiCyte® Triage for Managing Sepsis
Debiopharm and Ascepion Pharmaceuticals, Inc. announce an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor,…
Debiopharm Presented Results at the ASCO 2012 Annual meeting – Results of Phase I study with Debio 0932, an oral…